



POSTER PRESENTATION

Open Access

High levels of DEK autoantibodies may predict early flare following cessation of anti-TNF therapy in juvenile idiopathic arthritis

Nirit Mor-Vaknin^{1*}, Miguel Rivas¹, Maureen Legendre², Y Yuanfang¹, Anne Johnson³, Bin Huang³, Yuki Kimura⁴, Lili Zhao¹, Steve Spalding⁵, Paula Morris⁶, Beth Gottlieb⁷, Karen Onel⁸, Judyann Olson⁹, Barbara Edelheit³, Michael Shishov¹⁰, Larry Jung¹¹, Elaine Cassidy¹², Sampath Prahalad¹³, Murray Passo¹⁴, Timothy Beukelman¹⁵, Jay Mehta¹⁶, Kara Schmidt¹⁷, Ed Giannini⁴, Daniel Lovell³, David Markovitz²

From 21st European Pediatric Rheumatology (PReS) Congress
Belgrade, Serbia. 17-21 September 2014

Introduction

The nuclear oncoprotein DEK is a biochemically distinct, pro-inflammatory protein that is a chemoattractant for neutrophils and T-cells. High levels of DEK autoantibodies have been found in several autoimmune diseases including juvenile idiopathic arthritis (JIA), but their role in disease pathogenesis is unclear.

Objectives

Since DEK and DEK autoantibodies can contribute to the development of immune complexes and joint inflammation, we suggest that DEK antibody levels can predict disease flare with discontinuation of anti-TNF therapy.

Methods

In 16 pediatric rheumatology centers, sera samples were collected from 137 children with polyarticular JIA on anti-TNF therapy. Therapy was stopped after 6 months for patients with clinically inactive disease (CID). Disease activity was then monitored for 14 months or until disease flare. DEK antibody levels were measured by ELISA in sera collected at time of enrollment, disease flare off therapy, or end of study. DEK antibody levels relative to healthy controls were calculated by area under the curve (AUC), expressed as unit-free ratios.

Results

103 female and 34 male patients with polyarticular JIA were enrolled, mean age 11.3 years and disease duration

of 5.0 years (77% were on etanercept, 18% adalimumab, 5% infliximab, and 40% concurrent methotrexate). 31 patients discontinued the study for various reasons, including loss of CID during therapy. 39 patients flared within 14 months of stopping therapy, but 67 subjects had no flare within those 14 months. In 89 patients' samples collected at the end of the study or at time of flare, DEK antibody levels compared to healthy controls ranged from -0.69 (some patients had lower antibody levels than did healthy controls) to 0.83, mean difference of 0.068 (Q1-Q3 of -0.25-0.28 and 0.025 (SD, 0.39). High levels of DEK antibodies, mean and SD of 0.164 ± 0.39 , with 95% confidence interval of (0.02, 0.31), were detected in 30 of the patients that flared within 14 months as compared to lower levels of DEK antibodies (-0.05 ± 0.39 , 95% confidence interval of (-0.15, 0.05)) measured in 59 of the patients with no disease flare for 14 months (Student-T, $P=0.016$). Thus, patients that experience flare within 14 months of stopping anti-TNF therapy have significantly increased levels of DEK antibodies compared to patients that maintained their CID till the end of the study.

Conclusion

In children with polyarticular JIA on anti-TNF therapy that maintain CID for at least 6 months while on therapy, high DEK antibody levels may correlate with flare within the first 14 months after stopping therapy. This study suggests that DEK antibody levels might predict the outcome of discontinuation of anti-TNF therapy.

¹University of Michigan, Ann Arbor, USA

Full list of author information is available at the end of the article

Disclosure of interest

N. Mor-Vaknin: None declared., M. Rivas: None declared., M. Legendre: None declared., Y. Yuanfang: None declared., A. Johnson: None declared., B. Huang: None declared., Y. Kimura: None declared., L. Zhao: None declared., S. Spalding: None declared., P. Morris: None declared., B. Gottlieb: None declared., K. Onel: None declared., J. Olson: None declared., B. Edelheit: None declared., M. Shishov Consultant for: Novartis, Amgen, L. Jung Consultant for: AbbVee, E. Cassidy: None declared., S. Prahalad: None declared., M. Passo: None declared., T. Beukelman Grant / Research Support from: Pfizer, Consultant for: Novartis, Genentech, UCB, McKesson Health Solutions, Crescendo, J. Mehta: None declared., K. Schmidt: None declared., E. Giannini: None declared., D. Lovell: None declared., D. Markovitz: None declared.

Authors' details

¹University of Michigan, Ann Arbor, USA. ²Infectious Diseases, University of Michigan, Ann Arbor, USA. ³Cincinnati Children's Hospital Medical Center, Cincinnati, USA. ⁴Joseph M. Sanzari Children's Hospital, Hackensack, USA. ⁵Cleveland Clinic, Cleveland, USA. ⁶Arkansas Children's Hospital, Little Rock, USA. ⁷Cohen Children's Medical Center, New York, USA. ⁸Comer Children's Hospital, Chicago, USA. ⁹Children's Hospital of Wisconsin, Milwaukee, USA. ¹⁰Phoenix Children's Hospital, Phoenix, USA. ¹¹Children's National Medical Center, Washington DC, USA. ¹²Children's Hospital of Pittsburgh, Pittsburgh, USA. ¹³Emory, Atlanta, USA. ¹⁴Medical University of South Carolina, Charlestown, USA. ¹⁵Children's Hospital of Alabama, Birmingham, USA. ¹⁶Children's Hospital at Montefiore, Bronx, USA. ¹⁷Kosair Children's Hospital, Louisville, USA.

Published: 17 September 2014

doi:10.1186/1546-0096-12-S1-P8

Cite this article as: Mor-Vaknin *et al.*: High levels of DEK autoantibodies may predict early flare following cessation of anti-TNF therapy in juvenile idiopathic arthritis. *Pediatric Rheumatology* 2014 **12**(Suppl 1):P8.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

